Amylyx Pharmaceuticals, Inc. entered into an Asset Purchase Agreement with Eiger BioPharmaceuticals, Inc. to acquire the rights, title, and interests in the development, manufacture, and commercialization of Avexitide for $35.1 million plus additional costs and liabilities.